Preliminary Program
Preliminary Program: SATURDAY MAY21
Psychiatric News
Volume 40 Number 4 page 5-6

8 a.m.-Noon

CME Courses 1-3

9 a.m.-4 p.m.

CME Courses 4-7

10 a.m.-5 p.m.

Registration/Course Enrollment Open APA Member Center Open Publishers' Bookfair Open

12:30 p.m.-3:30 p.m.

Industry-Supported Symposia IS1. Anxiety: Diverse Populations and Presentations, Unique Individuals and TreatmentsSupported by UCB Pharma Inc.

A. Untangling the Role of Gender: The Course and Treatment of Anxiety Disorders in Women Naomi M. Simon, M.D.

B. Evaluation and Treatment of Anxiety in Patients With Comorbid Mental Illness Peter P. Roy-Byrne, M.D.

C. Improving Treatment of Anxiety, One Individual at a Time Jerrold F. Rosenbaum, M.D.

D. Bridging Cultures and Languages: Modifying Therapy for Refugees With PTSD Michael W. Otto, Ph.D.

E. Anxiety and Substance Abuse: Complexities and Solutions Kathleen T. Brady, M.D.

IS2. The Impact of Depression and Anxiety on Well-Being Across the Life CycleSupported by Pfizer Inc.

A. Comorbid Depression and Anxiety: When to Start and Continue With Psychotherapy and Pharmacotherapy Martin B. Keller, M.D.

B. Depression and Anxiety as They Relate to Asthma in Children Marcia J. Slattery, M.D.

C. Depression and Anxiety in Elderly Patients With Dementia Davangere P. Devanand, M.D.

D. Depression and Anxiety as They Relate to Cardiovascular Illness K. Ranga R. Krishnan, M.D.

E. Impact of Depression and Anxiety in Women of Reproductive Age Ruta M. Nonacs, M.D.

IS3. Management of Disruptive Behavioral and Pervasive Developmental DisordersSupported by Janssen Pharmaceutica and Research Foundation

A. The Unmet Treatment Needs of Youth With Severe Behavioral Problems David J. Posey, M.D.

B. Pharmacological Management of Aggression in Disruptive Behavior Disorders Robert L. Findling, M.D.

C. Pharmacotherapy of Behavioral Symptoms in Pervasive Developmental Disorders Christopher J. McDougle, M.D.

D. Nonpharmacological Approaches to the Management of Behavioral Symptoms Elizabeth Pappadopulos, Ph.D.

1 p.m.-5 p.m.

CME Courses 8-12

6 p.m.-9 p.m.

Industry-Supported Symposia IS4. Psychosomatic Illness: A 21st-Century PerspectiveSupported by GlaxoSmithKline

A. Impact of Anxiety and Mood Disorders on Physical Disease: The Worried Not-So-Well Murray B. Stein, M.D.

B. Facilitating Treatment for Anxious Patients With Comorbid Medical Illness Peter P. Roy-Byrne, M.D.

C. Chronic Pain Syndromes: A Psychiatric Perspective Prakash S. Masand, M.D.

D. Interface of Women's Mental and Reproductive Health Hadine Joffe, M.D.

IS5. The Developmental Trajectory of ImpulsivitySupported by Ortho-McNeil Pharmaceuticals

A. Comorbidities of Impulse Control Disorder Across the Lifespan Eric Hollander, M.D.

B. The Relationship of Trauma and Impulsivity in PTSD Lori L. Davis, M.D.

C. Potential Treatment for Impulsivity: Drive Versus Brake Larry J. Siever, M.D.

D. Bipolar Disorder From Adolescence to Adulthood Melissa P. DelBello, M.D.

E. Adolescent Substance Abuse and Impulse Dyscontrol Deborah Deas, M.D.

IS6. Integrating Neurobiology and Psychopathology Into Evidence-Based Treatment of Social Anxiety DisorderSupported by Forest Laboratories Inc.

A. Social Anxiety Disorder: Epidemiology, Diagnosis, and Comorbidities Michael R. Liebowitz, M.D.

B. Recent Recent Advances in the Cognitive Neuroscience of Social Behavior Philip T. Ninan, M.D.

C. Neurobiological Mechanisms of Social Anxiety Disorder Franklin R. Schneier, M.D.

D. Evidence-Based Pharmacotherapy of Social Anxiety Disorder Carlos Blanco-Jerez, M.D.

IS7. Bipolar Disorder: Psychiatric and Management Implications for Optimal Patient ManagementSupported by Pfizer Inc.

A. Psychiatric Comorbidity in Bipolar Disorder Susan L. McElroy, M.D.

B. Bipolar Disorder Complicated by Medical Comorbidity Roy H. Perlis, M.D.

C. Treatment and Monitoring Guidelines for the Patient With Bipolar Disorder Trisha Suppes, M.D.

D. Management of the Complicated Bipolar Patient Paul E. Keck, Jr., M.D.

IS8. Expanding Uses of Atypical Antipsychotics: Addressing Real-World ChallengesSupported by Bristol-Myers Squibb Company

A. Different Pharmacology of Antipsychotic Agents: Clinical Implications Jeffrey A. Lieberman, M.D.

B. Use of Antipsychotic Medications in Children Karen D. Wagner, M.D.

C. Managing Psychosis in the Acute Care Setting John E. Kraus Jr., M.D.

D. Improving Neurocognition With Atypical Antipsychotics Richard S. E. Keefe, Ph.D.

IS9. Achieving Remission in Depression: Is the Bar Set Too High or Too Low?Supported by Cephalon Inc.

A. Remission in Depression: Definitions and Treatment Approaches Joshua A. Israel, M.D.

B. Augmentations and Combination Strategies in Partial and Nonresponders to Antidepressants Charles DeBattista, M.D.

C. The Role of Psychotherapy to Enhance the Efficacy of Antidepressants Timothy J. Petersen, Ph.D.

D. Pharmacologic Approaches to the Treatment of Residual Symptoms in Depression Maurizio Fava, M.D.

E. Neurotherapeutics in Resistant Depression Linda L. Carpenter, M.D.

IS10. Dealing With Depression: The Added Burden to Medical PatientsSupported by Eli Lilly and Company

A. General Medical Comorbidities Associated With Depression Wayne J. Katon, M.D.

B. The Impact of Psychosomatic Symptoms on Depression and Its Treatment David A. Fishbain, M.D.

C. Strategies and Tactics for Treatment for Complicated Depression: An Algorithmic Approach Madhukar H. Trivedi, M.D.

D. The Role of Psychotherapy in the Treatment of Complicated Depression Ellen Frank, Ph.D.

E. Maintaining Remission in Depression James M. Martinez, M.D.

Interactive Graphics


Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Articles